Influence of Contrast Media on Bone Mineral Density (BMD) Measurements from Routine Contrast-Enhanced MDCT Datasets using a Phantom-less BMD Measurement Tool

Einfluss der intravenösen Kontrastmittelgabe auf phantomlose Knochendichtemessungen im Routine-MDCT

Authors
Andrea Toelly¹, Constanze Bardach¹, Michael Weber¹, Rui Gong², Yanbo Lai², Pei Wang², Yulin Guo², Jan Kirschke³, Thomas Baum⁴, Michael Gruber¹

Affiliations
1 Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Austria
2 Department of Radiology, General Hospital of Ningxia Medical University, Yinchuan, China
3 Department of Neuroradiology, Technical University Munich, Germany
4 Department of Diagnostic and Interventional Radiology, Technical University Munich, Germany

Key words
phantom-less, routine CT, contrast agents, calculation formula, bone mineral density

received 02.11.2016
accepted 21.01.2017

Bibliography
DOI http://dx.doi.org/10.1055/s-0043-102941
Published online: 26.4.2017 | Fortschr Röntgenstr 2017; 189: 537–543 © Georg Thieme Verlag KG Stuttgart · New York
ISSN 1438-9029

Correspondence
Dr. Andrea Toelly
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna
Waehringer Guertel 18–20
1090 Wien
Austria
Tel.: +43/40 404 0481 80
andrea.toelly@meduniwien.ac.at

ZUSAMMENFASSUNG
Ziel

Material und Methodik
112 postmenopausale Frauen im Alter von 40 bis 77 Jahren (mittleres Alter 57,31; SD 9,61), die ein triphasisches MDCT (nativ, arteriell und venös) auf Grund einer anderen klinischen Indikation erhalten haben, wurden inkludiert. Retrospektiv wurden mit Hilfe einer Software zur phantomlosen volumetrischen Knochendichtebestimmung die Knochendichtewerte der Wirbelkörper Th12 bis L4 bestimmt.

Ergebnisse
Der mittlere Knochendichtewert in der nativen Phase betrug 79,76 mg/cm³ (SD 31,20), in der arteriellen Phase 85,09 mg/cm³ (SD 31,61) und in der venösen Phase 86,18 mg/cm³ (SD 31,30). Es zeigte sich ein signifikanter Unterschied (p < 0,001) zwischen Knochendichtewerten in der nativen vs. Knochendichtewerten, welche in der arteriellen und venösen Phase gemessen wurden. Der Unterschied zwischen arteriell und venös gemessenen Knochendichtewerten war jedoch nicht signifikant (p = 0,228). Mittels linearer Regression konnte eine Formel zur Berechnung der wahrheitsgetreuen Knochendichte bei arteriell und venös gemessenen Knochendichtewerten aufgestellt werden: Knochendichte = −2,287 + 0,964 * [arteriell gemessener Knochendichtewert] und =−4,517 + 0,978 * [venös gemessener Knochendichtewert]. Die Intraobserver-Variabilität wurde mit einem Intraklassen-Korrelationskoeffizienten (ICC) von 0,984 berechnet. Der ICC für die Interobserver-Variabilität betrug 0,991.

Schlussfolgerung

Kernaussagen
- Knochendichtewerte können mittels spezieller Software an phantomlosen Routine-MDCTs bestimmt werden.
- Intravenöses Kontrastmittel führt zu einer signifikanten Steigerung der an Routine-CT-Untersuchungen gemessenen Knochendichtewerte.
Introduction

Osteoporosis is characterized by a lowered bone mass and trabecular thinning, which leads to an increased risk of fracture, higher mortality, and increased healthcare costs. In addition, patients with osteoporosis suffer from decreased independence and quality of life [1-4].

Osteoporosis is diagnosed by the assessment of bone mineral density (BMD). Commonly used BMD measurements are dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography (QCT). A major problem with DXA is that in elderly populations lumbar spine spondylosis causes false elevation of BMD when measured in this anatomical site [2, 5-8].

Recent studies have shown that routinely performed multidetector computed tomography (MDCT) scans can also be used for BMD measurements [9, 10]. As MDCT is one of the most important radiological examination methods, especially in tumor patients, and oncology patients also frequently suffer from osteoporosis triggered by chemotherapy or hormonal therapy, BMD measurements obtained on routine MDCT scans would be a promising method for the diagnosis of osteoporosis [11, 12]. A very recent innovation in this field was the development of phantomless BMD measurement systems. The major advantage of this phantomless BMD measurement system is that the patient can be used in his/her own reference, so that no bone equivalent phantom is necessary, and, consequently, BMD can be measured retrospectively on MDCT scans initially performed for another reason. This saves the patient from additional radiation exposure. Furthermore, beam-hardening and scatter effects, which might be induced by an external phantom, do not play a role in phantomless BMD measurement methods [13, 14].

However, it must be stated that there are potential problems with phantomless BMD methods. For example, heterogeneous or varying density values of muscle and fat, which are used as reference standards, due to differences in hydration status can influence the measurements [14]. In accordance with that, previous studies have already shown that intravenous contrast media administration also leads to higher BMD values measured on routine MDCT scans [15-18]. As oncologic staging investigations are mainly performed with the use of an intravenous contrast agent, this could be a major drawback for the diagnosis of osteoporosis on routine MDCT scans.

Therefore, the aim of our study was to evaluate the differences in phantomless BMD measurements on routine MDCT scans in the unenhanced, arterial, and venous contrast phases, using the Philips BMD measurement tool (Philips Healthcare, Best, NL). Furthermore, an algorithm for calculating a reliable BMD value from these contrast-enhanced MDCT scans should be developed.
Materials and Methods

Patients

In this prospective study, we included 112 female, postmenopausal patients from the age of 40 to 77 years (mean age: 57.31 years; SD 9.61), who underwent a routinely performed contrast-enhanced MDCT scan for other indications in the period from November 2013 to June 2014. The inclusion criteria were a contrast-enhanced MDCT scan, consisting of at least an unenhanced, an arterial and a venous phase, and a scan region including vertebrae T12 to L4. A flowchart of excluded patients is depicted in Fig. 1. Indications for the MDCT scans were, for example, nausea, abdominal pain, portal venous thrombosis and intestinal obstruction as well as follow-up examinations for ovarian, colon, gastric and lung cancer. In total, 61 patients were oncologic patients, 59 of which were undergoing chemotherapy. 6 patients were smokers. Only vertebrae T12 to L4 were included in the BMD analyses. Patients with metastases or hematologic or metabolic bone disorders besides osteoporosis were excluded. Furthermore, 16 vertebrae with benign osteolytic or osteoblastic lesions, for example, hemangiomas, 17 fractured vertebrae, and 4 vertebrae with pronounced degenerative changes were excluded. In one patient we had to exclude one vertebra because of a vertebroplasty. In total, at least two vertebrae in each patient had to be evaluable.

All patients gave written, informed consent to scientific evaluation of their data. The local ethics committee approved this prospective study.

Image acquisition

The MDCT scans were performed on a 256-row CT unit (Philips iCT 256, Philips Healthcare, Best, NL). The scanning protocol was adapted to the clinical indications. The images were acquired with a tube voltage of 120 kV, an average tube current of 200 mAs, and a collimation of 128 × 0.625 mm. Examinations were performed using contiguous acquisition (no overlap). Axial slices were reconstructed using a soft-tissue kernel and a slice thickness of 5 mm. Zips or metal clips were avoided in the field of view (FOV). For the contrast-enhanced series, we chose a standardized amount of contrast agent. Each patient received 100 ml of intravenous contrast media (Omnipaque 300 mg/ml, GE Healthcare, Little Chalfont, UK). For the injection, we used a Medrad injector with a flow rate of 3.0 ml/second. The intravenous contrast media injection started with a delay of 35 seconds for the arterial phase and 70 seconds for the venous phase. Only MDCT scans including unenhanced, arterial, and venous phases were included.

Image analyses

The BMD analyses were performed on a workstation, on which the required phantom-less Philips bone mineral density application was installed previously.

Initially, the correct slice and height of the region of the vertebral body, which should be measured at a safe distance from the cortical bone and tilted to the axis of the vertebra, was adjusted in the axial, coronal, and sagittal planes. An oval region of interest (ROI) was placed in the vertebral body on the axial plane, without including cortical bone and basivertebral veins. Subsequently, a second ROI was placed in the paravertebral muscle and a third ROI in the subcutaneous fat tissue (Fig. 2, 3). If the paravertebral muscle showed fatty atrophy of more than 50%, the second ROI was placed in the psoas muscle.

The BMD was calculated according to an algorithm that is implemented in the phantom-less BMD measurement tool [14]. All vertebrae were analyzed in each phase, including the unenhanced, arterial, and venous phases.

The calculated BMD value for each evaluated vertebra and each phase as well as the mean BMD values of all evaluated vertebrae for each individual patient in all phases were documented.

The bone mineral density application also provided a graph, in which the patient’s average BMD value was shown in relation to a European reference group (Fig. 4).
After a training session with a board-certified radiologist, a medical student in the last academic year performed all BMD evaluations. The BMD application’s reproducibility was evaluated using 40 randomly selected patients who were also evaluated by a resident in the third year of training. In order to calculate the intrarater agreement, the medical student evaluated 40 patients twice, blinded to patient-identifying data and previously measured BMD values.

Statistical analyses
All statistical analyses were performed by a statistician, using IBM SPSS 22.0.

BMD was described using mean and standard deviation. In order to compare BMD obtained on unenhanced scans and in the arterial and venous phases, repeated measures ANOVA and post hoc Bonferroni corrected paired t-tests were used. By using the linear regression analyses, two conversion formulas for the calculation of BMD values based on the contrast-enhanced phases could be developed. The intra- and interobserver agreement was rated using the intraclass correlation coefficient (ICC). A p-value of p < 0.05 was considered to indicate significant results.

Results
Calculating the mean BMD of at least two vertebrae per patient, the mean BMD value of all patients in the unenhanced phase was 79.76 mg/cm³ (SD 31.20). In the arterial phase, the mean BMD value of the whole study population was 85.09 mg/cm³ (SD 31.61), and, in the venous phase, the mean BMD value was calculated at 86.18 mg/cm³ (SD 31.30).
Repeated measures ANOVA and post hoc corrected paired t-tests showed that BMD values measured in the unenhanced phase were significantly lower than the values acquired in the venous and arterial phases (p < 0.001). However, there was no significant difference found between BMD values calculated in the arterial phase and BMD values measured in the venous phase (p = 0.228). Patients undergoing chemotherapy vs. patients without chemotherapy did not demonstrate any significant difference in regard to BMD values (p = 0.123). The same applies for smokers and non-smokers (p = 0.200).

Fig. 5a, b visualize a positive correlation when comparing BMD values calculated in the unenhanced MDCT scans versus BMD values measured in the arterial phase (a), and unenhanced measurements versus BMD values in the venous phase (b), without showing outliers. The difference between arterial and unenhanced BMD values, relative to the difference between venous and unenhanced BMD values, is depicted in Fig. 6.

Finally, two conversion formulas, enabling calculation of the unenhanced, relatively true BMD value from values measured in the arterial or venous phase, were defined using linear regression:
- Arterial phase: BMD = –2.287 + 0.964 * arterial BMD value
- Venous phase: BMD = –4.517 + 0.978 * venous BMD value

The intrarater agreement of BMD measurements was calculated with an intraclass correlation coefficient (ICC) of 0.984 and the interrater reliability was calculated with an ICC of 0.991.

Discussion

Our study showed that phantom-less BMD measurements on contrast-enhanced MDCT scans are possible, even though intravenous contrast agent elevates BMD values, which can result in falsely high results. Taking this into account, it is possible to calculate a converted BMD value using the formulas defined in this study.

In comparison to the suggested thresholds for osteoporosis (< 80 mg/cm³) and osteopenia (> 80 to 120 mg/cm³) issued by the American College of Radiology, a remarkable observation in our study was the generally low BMD values of our patients, which might be a population-related finding, as former studies have shown lower BMD values in this ethnic population compared to other ethnic populations [19, 20]. Since we included 59 patients receiving chemotherapy and 6 smokers, which may have an impact on BMD measurements, an additional statistical analysis was conducted: chemotherapy or smoking did not significantly influence BMD values. In addition, a software-related origin is possible, as Mueller et al. also found slightly lower BMD values using the Philips BMD option compared to phantom-based QCT. However, in their study, the values measured by the BMD software were generally only 0.9 mg/cm³ lower than the BMD values calculated by phantom-based QCT, which is a negligibly low difference. Furthermore, they demonstrated a slightly lower precision compared with phantom-based QCT, but, nevertheless, a very good accuracy of the Philips bone mineral density application, with some advantages compared to QCT using a phantom [14].

With regard to phantom-based QCT, a major disadvantage of the method is the need for a phantom. Using the Philips bone mineral density option, no phantom is needed and BMD measurements can be performed retrospectively in any patient who underwent a CT scan for any reason, without the need for another investigation that might cause additional radiation exposure. Furthermore, the phantom-less BMD measurement is a time- and cost-saving method [14, 21].

Previous studies have already investigated the possibility of BMD measurements on routinely performed MDCT scans and the influence of intravenous contrast agent on the measured BMD values [10, 15, 16, 18, 22, 23]. These studies used different methods
and showed somewhat divergent outcomes: Pompe et al. measured attenuation values of L1 in different contrast agent phases and found a significant difference between all phases [15]. In contrast, Pickhardt et al. compared Hounsfield Unit (HU) values of L1 on pre-contrast CT scans with measurements on contrast-enhanced CT scans and did not find a significant difference [10, 22]. Some studies, such as the one by Bauer et al., used QCT for BMD evaluation. These investigators described a 2 % increase in BMD values measured in the hip after intravenous contrast agent administration versus a 31 % increase in BMD values measured in the spine [18]. These results correspond very well with the results defined by Link et al., who noted an increase of 30 % in BMD values measured in the spine after intravenous contrast agent administration [16]. Baum et al. compared routine MDCT with a phantom to dedicated phantom-based QCT, and also found an average increase in BMD values of 37.9 %, measured in the spine, compared to QCT values [23]. A potential problem when using a phantom-less BMD measurement method, where the patient serves as his/her own reference, might be the variable contrast enhancement of bone, as well as muscle and fat tissue, which leads to increased HU values of all measurements, and thus, may falsify the calculation algorithm.

Our study has some limitations. We did not correlate our results with the presence of vertebral fractures, as outlined by Baum et al. [23]. Furthermore, the ROIs were placed manually, which gives rise to the risk of a lower precision and a higher inter- and intraobserver variability. We minimized that risk by providing both observers with an intensive training session before starting the study, thus helping to achieve a very low inter- and intraobserver variability. In contrast to other studies like those of Pompe et al. or Pickhardt et al., our technique requires a specific software tool, which entails additional costs [10, 15]. Another limitation of this study is that no additional DXA or QCT examinations were available as a reference or for comparison.

Conclusion

In conclusion, routinely performed contrast-enhanced abdominal MDCT scans can be used for BMD measurement using our method, but the administration of contrast agent should be taken into account. The two formulas defined in this study enable the measurement of BMD values on contrast-enhanced MDCT scans because the actual BMD value can be calculated afterward. The Philips bone mineral density measurement tool used in our study showed very good reliability and seems to be a promising phantom-less method for retrospective BMD measurements on routine MDCT scans.

CLINICAL RELEVANCE OF THE STUDY

- Using the phantom-less Philips bone mineral density measurement tool tested in this study, BMD measurements can be done retrospectively on any MDCT scan performed for another reason.
- Intravenous contrast media application increases BMD values measured in the arterial as well as venous phases.
- Applying the formulas defined in this study, a reliable BMD value can be calculated from BMD values measured in the arterial or venous phase.

Conflict of Interest

The authors declare that they have no conflict of interest.

References


